RAPT Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $18.61
- Today's High:
- $19.24
- Open Price:
- $18.61
- 52W Low:
- $15.585
- 52W High:
- $31.45
- Prev. Close:
- $18.57
- Volume:
- 207680
Company Statistics
- Market Cap.:
- $692.32 million
- Book Value:
- 5.813
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $1.53 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -29.94%
- Return on Equity TTM:
- -49.15%
Company Profile
RAPT Therapeutics Inc had its IPO on 2019-10-31 under the ticker symbol RAPT.
The company operates in the Healthcare sector and Biotechnology industry. RAPT Therapeutics Inc has a staff strength of 122 employees.
Stock update
Shares of RAPT Therapeutics Inc opened at $18.61 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $18.61 - $19.24, and closed at $19.
This is a +2.32% increase from the previous day's closing price.
A total volume of 207,680 shares were traded at the close of the day’s session.
In the last one week, shares of RAPT Therapeutics Inc have slipped by -5.71%.
RAPT Therapeutics Inc's Key Ratios
RAPT Therapeutics Inc has a market cap of $692.32 million, indicating a price to book ratio of 3.0609 and a price to sales ratio of 266.1551.
In the last 12-months RAPT Therapeutics Inc’s revenue was $0 with a gross profit of $1.53 million and an EBITDA of $-104955000. The EBITDA ratio measures RAPT Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, RAPT Therapeutics Inc’s operating margin was 0% while its return on assets stood at -29.94% with a return of equity of -49.15%.
In Q2, RAPT Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
RAPT Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.84 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into RAPT Therapeutics Inc’s profitability.
RAPT Therapeutics Inc stock is trading at a EV to sales ratio of 171.648 and a EV to EBITDA ratio of -5.0002. Its price to sales ratio in the trailing 12-months stood at 266.1551.
RAPT Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $220.76 million
- Total Liabilities
- $15.41 million
- Operating Cash Flow
- $32.44 million
- Capital Expenditure
- $233000
- Dividend Payout Ratio
- 0%
RAPT Therapeutics Inc ended 2024 with $220.76 million in total assets and $0 in total liabilities. Its intangible assets were valued at $220.76 million while shareholder equity stood at $199.68 million.
RAPT Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $15.41 million in other current liabilities, 3000.00 in common stock, $-422435000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $50.16 million and cash and short-term investments were $205.00 million. The company’s total short-term debt was $2,333,000 while long-term debt stood at $0.
RAPT Therapeutics Inc’s total current assets stands at $207.42 million while long-term investments were $0 and short-term investments were $154.83 million. Its net receivables were $0 compared to accounts payable of $2.69 million and inventory worth $0.
In 2024, RAPT Therapeutics Inc's operating cash flow was $32.44 million while its capital expenditure stood at $233000.
Comparatively, RAPT Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $19
- 52-Week High
- $31.45
- 52-Week Low
- $15.585
- Analyst Target Price
- $40.58
RAPT Therapeutics Inc stock is currently trading at $19 per share. It touched a 52-week high of $31.45 and a 52-week low of $31.45. Analysts tracking the stock have a 12-month average target price of $40.58.
Its 50-day moving average was $21.01 and 200-day moving average was $21.42 The short ratio stood at 14.98 indicating a short percent outstanding of 0%.
Around 190.6% of the company’s stock are held by insiders while 10038.3% are held by institutions.
Frequently Asked Questions About RAPT Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company’s lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.